Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Rating of “Buy” from Brokerages

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have received an average recommendation of “Buy” from the eleven brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $66.00.

A number of equities research analysts have recently weighed in on the company. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Finally, Truist Financial cut their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th.

Maze Therapeutics Trading Up 0.1%

Shares of NASDAQ:MAZE opened at $27.31 on Wednesday. The company has a market cap of $1.51 billion, a PE ratio of -10.79 and a beta of 2.21. The company’s 50-day moving average price is $27.63 and its 200 day moving average price is $33.32. Maze Therapeutics has a fifty-two week low of $12.81 and a fifty-two week high of $53.65. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). Sell-side analysts anticipate that Maze Therapeutics will post -2.73 earnings per share for the current year.

Insider Activity

In related news, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the completion of the transaction, the chief executive officer owned 23,337 shares in the company, valued at $699,643.26. This represents a 59.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 15,000 shares of the firm’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $26.22, for a total transaction of $393,300.00. Following the transaction, the chief marketing officer directly owned 15,000 shares in the company, valued at approximately $393,300. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 141,470 shares of company stock valued at $3,902,714. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. TRV GP V LLC acquired a new position in shares of Maze Therapeutics during the second quarter valued at approximately $28,371,872,000. TRV GP IV LLC acquired a new stake in Maze Therapeutics in the second quarter worth approximately $133,502,907,000. BlackRock Inc. bought a new position in Maze Therapeutics during the 2nd quarter valued at $104,525,000. Deutsche Bank AG acquired a new position in shares of Maze Therapeutics during the 2nd quarter valued at $1,044,000. Finally, Alphabet Inc. acquired a new position in shares of Maze Therapeutics during the 2nd quarter valued at $41,435,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.